Clinical Medicine Insights: Oncology

Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?

Submit a Paper

Clinical Medicine Insights: Oncology 2011:5 325-332

Consise Review

Published on 20 Oct 2011

DOI: 10.4137/CMO.S5977

Further metadata provided in PDF

Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Insights: Oncology

The Editor-in-Chief has endorsed this article

Therapeutic advances changed dramatically in 2010 with the U.S. FDA approval of the autologous cellular immunotherapy sipuleucel-T for the treatment of men with asymptomatic or minimally symptomatic metastatic CRPC. This is an updated review on the data regarding therapeutic options with particular focus on the emerging strategies for incorporating sipuleucel-T into this changing landscape.

Post a Comment

x close

Discussion Add A Comment
No comments yet...Be the first to comment.

Quick Links

New article and journal news notification services